Brian Mueller - Apr 29, 2022 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
EVP, Chief Financial Officer
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
Apr 29, 2022
Transactions value $
-$533,854
Form type
4
Date filed
5/6/2022, 07:45 PM
Previous filing
Mar 17, 2022
Next filing
Jul 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Award $21.2K +340 +0.89% $62.41 38.6K Apr 29, 2022 Direct F1
transaction BMRN Common Stock Options Exercise $76.3K +2.04K +5.27% $37.46 40.7K May 4, 2022 Direct F2
transaction BMRN Common Stock Sale -$172K -2.04K -5.01% $84.50 38.6K May 4, 2022 Direct F2
transaction BMRN Common Stock Options Exercise $366K +9.76K +25.26% $37.46 48.4K May 4, 2022 Direct F2
transaction BMRN Common Stock Sale -$825K -9.76K -20.17% $84.50 38.6K May 4, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -2.04K -100% $0.00* 0 May 4, 2022 Common Stock 2.04K $37.46 Direct F2, F3
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -9.76K -100% $0.00* 0 May 4, 2022 Common Stock 9.76K $37.46 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired by the reporting person on April 29, 2022, pursuant to the issuer's Employee Stock Purchase Plan.
F2 Trade made pursuant to a 10b5-1 plan executed on March 14, 2022.
F3 Reflects the number of options outstanding after the transactions from this specific stock option grant.